|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
|
|
SIDE EFFECTS:
|
|
Pseudo-allergic reaction |
|
Dizziness |
|
headache |
|
nausea |
|
Changes in taste |
|
chest pains |
|
CNS effects |
|
diarrhea |
|
dryness of mouth |
|
pain at injection site |
|
vasodilation |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
>> Allergies or asthma |
|
Anemia, hemolytic |
|
>> Renal function impairment, severe |
|
>> Sensitivity to gadodiamide |
|
Sickle cell disease |
|
|
ADULT DOSE:
|
|
Brain and spinal lesions imaging, magnetic resonance-
Intravenous, by direct injection (at a rate >60 mL per minute), 0.2 mL (0.1 mmol) per kg of body weight.
Note: To insure complete injection of gadodiamide, a 5-mL flush using 0.9% sodium chloride injection should be administered following injection of gadodiamide.
If repeat examinations are required, an interval of time should elapse between injections to allow for normal clearance of gadodiamide. |
|
MAXIMUM ADULT DOSE:
|
|
Up to a total dose of 5.74 grams (20 mL).
|
|
PEDIATRIC DOSE:
|
|
Brain and spinal lesions imaging, magnetic resonance-
Dosage must be individualized by physician.
Note: Doses based on 0.2 mL (0.1 mmol) of gadodiamide per kg of body weight have been used in pediatric patients. |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
Brain and spinal lesions imaging, magnetic resonance-
Intravenous, by direct injection (at a rate >60 mL per minute), 0.2 mL (0.1 mmol) per kg of body weight.
Note: To insure complete injection of gadodiamide, a 5-mL flush using 0.9% sodium chloride injection should be administered following injection of gadodiamide.
If repeat examinations are required, an interval of time should elapse between injections to allow for normal clearance of gadodiamide. |
|
|
|
|